MSD said on April 16 that it has filed a smaller easier-to-swallow tablet version of its oral COVID-19 treatment Lagevrio (molnupiravir) in Japan. The drug is currently only available in a capsule form. With the new version, a single tablet…
To read the full story
Related Article
- MSD Started Work to Develop Easier-to-Swallow Form of Lagevrio: Exec
October 20, 2022
BUSINESS
- Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
- Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
- Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
- Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026
- Minimum Price Hike, Spillover Abolition Win Industry Support in FY2026 Reform: Jiho Poll
March 10, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





